Arun Rajan
National Cancer Institute (NCI) · National Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arun Rajan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07902921 · STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaNational Cancer Institute (NCI) · not yet recruiting · NSCLC, Non-Small Cell Lung Cancer, Lung Cancer · principal investigator
- Ph2NCT05104736 · PT-112 in Subjects With Thymoma and Thymic CarcinomaNational Cancer Institute (NCI) · recruiting · Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer · principal investigator
- Ph2NCT04417660 · Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaNational Cancer Institute (NCI) · active not recruiting · Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer · principal investigator
- Ph2NCT03896503 · Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the LungsNational Cancer Institute (NCI) · active not recruiting · Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma · principal investigator
- Ph2NCT03076554 · A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyNational Cancer Institute (NCI) · active not recruiting · Thymoma, Thymic Carcinoma · principal investigator
- N/ANCT02146170 · Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsNational Cancer Institute (NCI) · recruiting · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer · principal investigator
- Ph2NCT01621568 · Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentNational Cancer Institute (NCI) · completed · Thymoma, Thymus Neoplasms · principal investigator
- Ph1NCT01445106 · A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid TumorsNational Cancer Institute (NCI) · completed · Solid Tumors · principal investigator
- Ph1NCT01441128 · -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell · principal investigator
- Ph2NCT01306045 · Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNational Cancer Institute (NCI) · completed · Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic · principal investigator
- Ph2NCT01301391 · Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of ChemotherapyTiziana Life Sciences LTD · terminated · Malignant Thymoma · principal investigator
- N/ANCT01255150 · Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Non-Small-Cell Lung Carcinoma · principal investigator
- Ph2NCT01229150 · Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...National Cancer Institute (NCI) · completed · Non Small Cell Lung Carcinoma · principal investigator
- Ph1/Ph2NCT01100944 · A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, MalignanciesNational Cancer Institute (NCI) · terminated · Thymoma, Thymic Carcinoma · principal investigator
- Ph2NCT01011439 · Phase II Study Of Oral PHA-848125AC In Patients With Thymic CarcinomaTiziana Life Sciences LTD · terminated · Thymic Carcinoma · principal investigator
- Ph2NCT00971789 · Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor SyndromesNational Cancer Institute (NCI) · completed · Cowden's Disease, Hamartoma Syndrome, Multiple · principal investigator
- Ph2NCT00965250 · Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With ChemotherapyNational Cancer Institute (NCI) · completed · Thymoma, Thymic Carcinoma, Thymic Carcinoid · principal investigator
- N/ANCT00923884 · Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung CancerNational Cancer Institute (NCI) · completed · Carcinoma, Non-Small Cell Lung, Carcinoma, Small-Cell Lung · principal investigator
- Ph1/Ph2NCT00923273 · Sirolimus and Pemetrexed to Treat Non-Small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph1/Ph2NCT00073398 · Vaccine Treatment for Advanced Non-Small Cell Lung CancerNewLink Genetics Corporation · completed · Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 7 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase II Trial of PT-112 in Subjects with Thymoma and Thymic CarcinomaZIABC012106 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 to 2025 · $477,167 awarded in 2025Same name and institution; not confirmed by an ID
- Anetumab in Thymic CarcinomaZIABC011902 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $35,345 awarded in 2025Same name and institution; not confirmed by an ID
- Anti-PD-L1-TGFb antibody (M7824) in advanced Non-Small Cell Lung CancerZIABC011905 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $176,728 awarded in 2025Same name and institution; not confirmed by an ID
- CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung CancerZIABC011906 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $17,673 awarded in 2025Same name and institution; not confirmed by an ID
- Durvalumab in Combination with Olaparib in Non-Small Cell Lung CancerZIABC011907 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $176,728 awarded in 2025Same name and institution; not confirmed by an ID
- Medical Oncology HIV-AIDS Clinical ResearchZIDBC011683 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 to 2025 · $749,159 awarded in 2025Same name and institution; not confirmed by an ID
- Medical Oncology Service Clinical CoreZIDBC011543 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 to 2025 · $4,245,233 awarded in 2025Same name and institution; not confirmed by an ID
- Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic CarcinomaZIABC012001 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2025 · $353,458 awarded in 2025Same name and institution; not confirmed by an ID
- Pilot Study of Avelumab in Thymic Epithelial TumorsZIABC011900 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $530,186 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:10 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 238 citationsRCR 7.1
- Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.J Clin Oncol · 2015188 citationsRCR 4.8
- Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Cell Rep Med · 2020173 citationsRCR 6.0
- 137 citationsRCR 3.6
- 118 citationsRCR 3.0
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Oncotarget · 201573 citationsRCR 1.9
- Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.Clin Cancer Res · 201161 citationsRCR 1.5
- Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.J Immunother Cancer · 202418 citationsRCR 1.5
- Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.J Thorac Oncol · 201117 citationsRCR 0.5
- Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.Int J Cancer · 202311 citationsRCR 0.8